

CURRICULUM VITAE

Frederick Feit, M.D.

Born: March 21, 1948
New York, New York

Education: *Primary:* Bronx, New York
Secondary: Bronx High School of Science 1964
Undergraduate: New York University 1968
Medical School: New York University School of Medicine 1972

Medical Training: *Intern in Medicine,*
Bellevue Hospital Center 1972-1973
Resident in Medicine,
Bellevue Hospital Center,
New York University Medical Center 1973-1975
Chief Resident in Medicine,
Bellevue Hospital Center,
New York University Medical Center 1975-1976
Cardiology Fellow,
Bellevue Hospital Center,
New York University Medical Center 1976-1978

Academic and Research Appointments: *Teaching Assistant,* Department of Medicine,
New York University School of Medicine 1973-1975
Instructor, Department of Medicine,
New York University School of Medicine 1975-1980
Assistant Professor of Medicine,
New York University School of Medicine 1980-1988
Associate Professor of Medicine,
New York University School of Medicine 1988-

Co-Principal Investigator, Randomized Trial on Non-Surgical Reperfusion During Myocardial Infarction (NIH-Sponsored - #1-RO1HL 28843-01) 1982-1985

1990

<i>Principal Investigator, NIH Multicenter Primary Pulmonary Hypertension Registry</i>	1982-1985
<i>Co-Investigator, Cardioprotective Effects of ICRF-187 in Patients Receiving Adriamycin (NIH Sponsored)</i>	1984-1988
<i>Principal Investigator, TIMI Trial Phase II Thrombolysis in Myocardial Infarction (NIH Sponsored)</i>	1986-
<i>Co-Principal Investigator, NIH Balloon Valvuloplasty Registry</i>	1987-
<i>Principal Investigator, Bypass Angioplasty Revascularization Investigation (BARI) (NIH Sponsored)</i>	1989-
<i>Principal Investigator, Multicenter Study of Thrombolytic Therapy in an Older Patient Population (TTOPP)</i>	1989-
<i>Co-Investigator, Multicenter Study of Pre-hospital Administration of tPA (PATS)</i>	1989-1991
<i>Co-Investigator, Study of Medical vs Angioplasty Reperfusion Therapy (SMART).</i>	1991-1992
<i>Co-Principal Investigator, Multicenter, Randomized Study of Hirulog and Heparin in Patients with Unstable Angina Undergoing PTCA</i>	1994-
<i>Principal Investigator, I.V.A.T.: The Intermediate Vessel Atherectomy Trial</i>	1996-1997
<i>Principal Investigator, Dilatation versus Atherectomy Revascularization Trial</i>	1996-1997
<i>Principal Investigator, ATLAST Trial: Anti-platelet Therapy vs. Lovenox plus antiplatelet therapy for patients with an increased risk of stent thrombosis (ATLAST)</i>	1996-1998
<i>Principal Investigator, AMP579-201, A double-blind placebo-controlled dose-ranging study to determine the safety and efficacy of AMP579 in patients with acute myocardial infarction treated with primary angioplasty</i>	1997-1998
<i>Principal Investigator, STENT P.A.M.I.: A randomized trial of primary PTCA versus heparin coated stent implantation during acute myocardial infarction</i>	1996-1998
<i>Investigator, PEACE Trial: Prevention of Ischemic Events with Angiotensin Converting Enzyme Inhibition</i>	1997-

Investigator, AIR-PAMI: A randomized trial of thrombolysis compared to transfer for acute myocardial intervention in high risk M.I. patients (AIR PAMI) with a No Surgery on Site (No S.O.S.) Registry 1997-

Sub-Investigator, A.V.I.D. Trial: Angiography Versus Intravascular Ultrasound-Directed (A.V.I.D.)coronary stent placement: Effect on long term outcome 1998-

Co-Principal Investigator, OPUS: Orbofiban in Patients with Unstable Coronary Syndromes (TIMI 16) 1998

Co-Principal Investigator, The CADILLAC Trial, A randomized comparison of the ACS Rx Multi-link coronary stent system with or without abciximab versus PTCA with or without abciximab in the treatment of patients for ischemic events 1998-

Principal Investigator, A multicenter, open-label, randomized trial comparing clinical outcome with hirulog and provisional abciximab versus planned abciximab and low-dose heparin in patients undergoing percutaneous intervention 1998-

Principal Investigator, Biocompatibles Bio-divYsio stent randomized control trial 1998-

Co-Principal Investigator, NYU Registry of clopidogrel and aspirin treatment in patients undergoing elective coronary stenting 1998-

Principal Investigator, A randomized double-blind, placebo-controlled, multicenter trial to evaluate the efficacy and safety of Adenosine as an adjunct to reperfusion therapy in the treatment of acute anterolateral myocardial infarction. 1999

**Hospital
Appointments:**

Attending Physician,
Bellevue Hospital Center,
New York University School of Medicine 1976-

Attending Physician,
New York University Hospital
New York University School of Medicine 1978-

Associate Director, Coronary Care Unit
Bellevue Hospital Center,
New York University School of Medicine 1978-

Associate Director, Cardiac Catheterization,

	Bellevue Hospital Center, New York University School of Medicine	1978-1979
	<i>Director</i> , Cardiac Catheterization, Bellevue Hospital Center, New York University School of Medicine	1979-
	Visiting Lecturer, Department of Medicine, Mt. Sinai School of Medicine	1982-
	<i>Director</i> , Cardiac Catheterization, New York University/Tisch Hospital, New York University School of Medicine	1994-
Certification and Licensure:	<i>Diplomate</i> , National Board of Medical Examiners	1973 1973
	New York State Medical License, #118181	
	<i>Diplomate</i> , American Board of Internal Medicine	1976
	<i>Diplomate</i> , American Board of Cardiovascular Diseases	1979
Societies and Honors:	<i>Letter of Commendation</i> , National Merit Scholarship Program	1964
	New York State Regents Scholarship	1964
	<i>National Science Foundation Grant</i> Awarded for Chemistry Research	1967
	<i>Founders Day Award</i> for Scholastic Excellence	1968
	Louis P. Hammet Award for Special Ability in Chemical Research	1968
	<i>Dean's List</i> , New York University	1965-1968
	Abraham and Frances Menaker Award for Excellence in Chemistry	1968
	<i>New York University Alumni Club Award</i> for Excellence in Chemistry	1968
	<i>Phi Beta Kappa</i>	1968
	Graduate <i>cum laude</i> , with Honors in Chemistry, New York University	1968
	<i>Fellow</i> , American College of Cardiology	1980
	<i>Alpha Omega Alpha</i>	1989
	<i>Outstanding Teacher Award</i> , Bellevue Hospital, Department of Medicine	1990
Major Committee	Emergency Services Committee, Bellevue Hospital Center	1980-

Assignments:

N.I.H. Committee for Selection of TIMI Trial Data Coordinating Center	1982
New York University Self-Study Committee Curriculum Committee, Cardiology Section, New York University School of Medicine	1983-
Thrombolysis in Myocardial Infarction (TIMI); Steering Committee, PTCA Committee, Hemorrhagic Events Review Committee	1986-
American Heart Association, 60th and 62nd Scientific Sessions; Chairman, session on ischemic heart disease	1987,1989
N.I.H. Balloon Valvuloplasty Registry; Executive Committee, Steering Committee	1988-
American Federation for Clinical Research; Chairman, Eastern Regional Section Meeting	1988
Bypass, Angioplasty Revascularization Investigation (BARI); Steering Committee, PTCA Committee	1989-
New York Heart Association Professional Education Committee	1989-
Thrombolytic Therapy in an Older Patient Population (TTOPP); Chairman, Steering Committee	1989-
American College of Cardiology Annual Scientific Session; Chairman, session on ischemic heart disease	1991
New York Heart Association Clinical Forums Director	1994-
American College of Cardiology Program Committee	1996
American College of Cardiology Annual Meeting: Organized all Sunday Minicourse Programs	1996
Scientific Advisor: Medicines Co.	1998

Editorial Boards:

Invited Reviewer for:	
Catheterization and Cardiovascular Diagnosis	1984-
Circulation	1986-
American Heart Association Abstracts	1987-
American College of Cardiology Abstracts	1989

Invited Presentations (Non-Abstract) at National Meetings:

American College of Cardiology,

Debate (vs. Harzell Schaff, MD): "Coronary Angioplasty is preferable to CABG for multivessel disease"	1993
American College of Cardiology, "TIMI II Revisited"	1994
American College of Cardiology Minicourse for Acute MI: Historical Perspective and Current Therapy	1996
American College of Cardiology, Meet the Experts: "Who should get rescue PTCA after thrombolytic therapy?"	1996
Society of Coronary Angiography and Intervention," Adjuvant Therapy for Unstable Angina	1998
Transcatheter Cardiovascular Therapeutics, Co-Chair, Controversies Session: Debate vs. James Tchong,MD--"The Use of Glycoprotein IIb/IIIa Inhibitors During Percutaneous Intervention"	1998
American College of Cardiology, ACCIS Arterial Access Complications, "Leg Ischemia"	1999

Invited Presentations at International Cardiology Meetings:

Italian Cardiology National Meeting Bologna, Italy	1983
"Thrombolytic Therapy for Acute MI" Escorts Hospital and Cardiovascular Research Institute, New Delhi, India	1998
"Interventional cardiology as we approach the next millenium"	
"Therapy of Acute MI from Evolution to Revolution"	

SELECTED PUBLICATIONS:

1. Goldstein IM, Feit F, Weissmann G. Enhancement of nitroblue tetrazolium dye reduction by leukocytes exposed to a component of complement in the absence of phagocytosis. *Journal of Immunology* 1975;114:516-518.
2. Feit F. The range of supraventricular tachycardias. *Emergency Medicine* 1982;14:148-175.
3. Feit F, Rentrop KP. Thrombolytic therapy during acute myocardial infarction. *Cardiovascular Reviews and Reports* 1983;4:426-444.
4. Rentrop KP, Feit F, Blanke H, et al. Effects of intracoronary streptokinase and intracoronary nitroglycerin infusion on coronary angiographic patterns and mortality in patients with acute myocardial infarction. *New Engl J Med* 1984;311:1457-1463.
5. Rentrop KP, Feit F. Intracoronary streptokinase for acute myocardial infarction. *N Engl J Med* 1985;313:78-790.
6. Murphy-Chutorian DR, Wexman MP, Grieco AJ, Heineger JA, Glassman E, Gaull GE, Ng SK, Feit F, et al. Methionine intolerance: A possible risk factor for coronary artery disease. *J Am Coll Cardiol* 1985;6:725-730.
7. Feit F, Rentrop P. Thrombolytic therapy in acute myocardial infarction. In *Harrison's Principles of Internal Medicine, Update VI*, McGraw-Hill 1985; pp.147-161.
8. Feit F, Strom J, Silverman R. A case of thrombolytic therapy and angioplasty following myocardial infarction. *Case Studies in Cardiac Emergencies* 1985;6(4):1-8.
9. Feit F, Stecy P, Nachamie M. Percutaneous balloon valvuloplasty for stenosis of a porcine bioprosthesis in the tricuspid valve position. *Am J Cardiol* 1986;58:363-364.
10. Freedberg RS, Friedman GR, Palu RN, Feit F. Cardiogenic shock due to antihistamine overdose: reversal with intra-aortic balloon counterpulsation. *JAMA* 1987;257:660-661.
11. Feit F, Goldberger MH, Silverman R. A case of thrombolytic therapy with rt-PA and angioplasty. *Case Studies in Cardiac Emergencies* 1987;8(3):1-8.
12. Rosenzweig BP, Kronzon I, Feit F, et al. Systolic antegrade tricuspid blood flow - a sign of severe prosthetic valve stenosis. *Am Heart J* 1988;115:693-6.
13. Rentrop P, Thornton J, Feit F, Van Buskirk M. Determinants and protective potential of coronary arterial collaterals as assessed by an angioplasty model. *Am J. Cardiol* 1988;61:677-684.

14. Levin RI, Feit F. The effect of aspirin on the hemodynamic response to nitroglycerin. *Am Heart J* 1988;116:77-84.
15. Speyer J, Green M, Kramer E, Rey M, Sanger J, Ward C, Dubin N, Ferrans V, Stecy P, Zeleniuch-Jacquotte A, Wernz J, Feit F, et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. *N Engl J Med* 1988;319:745-52.
16. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. *N Engl J Med* 1989;320:618-627.
17. Rentrop KP, Feit F, Sherman W, et al. Late thrombolytic therapy preserves left ventricular function in patients with collateralized total coronary occlusion: primary endpoint findings of the second Mt. Sinai-NYU reperfusion trial. *J Am Coll Cardiol* 1989;14:58-64.
18. Rentrop KP, Feit F, Sherman W, Thornton J. Serial angiographic assessment of coronary obstruction and collateral flow in acute myocardial infarction. Report from the second Mt. Sinai-NYU reperfusion trial. *Circulation* 1989;80:1166-1175.
19. Goldfarb A, King CO, Rosenzweig BR, Feit F, et al. Cardiac lymphoma in the acquired immunodeficiency syndrome. *Am Heart J* 1989;118:1340-1344.
20. Attubato M, Stroh J, Slater J, Bach RS, Feit F. Percutaneous double-balloon valvuloplasty of tricuspid porcine bioprosthetic valves. *Cathet Cardiovasc Diag* 1990;20:202-4.
21. Baim DS, Braunwald E, Feit F, et al. The TIMI-II trial: reflections and further considerations. *J Am Coll Cardiol* 1990;15:1188-92.
22. Attubato M, Feit F. Tissue plasminogen activator. In Anderson JL (editor): *Modern Management of Acute Myocardial Infarction in the Community Hospital*. New York, Marcel Dekker, Inc; 1991:217-249.
23. Galloway AC, Feit F. Acute myocardial infarction. In *Surgical Decision Making, Third Edition*; In press.
24. Feit, F, Mueller H, Braunwald E, et al. Thrombolysis in myocardial infarction (TIMI) phase II trial: outcome comparison of a "conservative strategy" in community versus tertiary hospitals. *J Am Coll Cardiol* 1990;16:1529-34.
25. Dean LA, Feit F, Stewart D, et al. Percutaneous mitral balloon commissurotomy: a report from the NHLBI balloon valvuloplasty registry. *Circulation*; Submitted.
26. Bovill E, Terrin M, Stump DC, Berke A, Bryant M, Collen D, Feit F, et al. Hemorrhagic events during treatment with intravenous recombinant tissue-type plasminogen activator in

acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) phase II trial. *Ann Int Med* 1991;115(4):256-65.

27. McKendall GR, Attubato MJ, Drew TM, Feit F, Sharaf DL, Thomas ES, Teichman S, McDonald MJ, Williams DO. Improved infarct artery patency using a new regimen of rt-PA: results of the prehospital administration of re-PA study (PATS) phase I. *J Am Coll Cardiol* 1991;18(7):1774-1778.
28. Katz ES, Cziner DG, Rosenzweig BP, Attubato MJ, Feit F, Kronzon I. Multifaceted echocardiographic approach to the diagnosis of a ruptured sinus of valsalva aneurysm. *J Am Soc Echo* 1991;4:494-498.
29. Baim DS, Diver DJ, Feit F, Greenberg, MA, Holmes DR, et al. Coronary angioplasty performed within the thrombolysis in myocardial infarction (TIMI II) study. *Circulation* 1992;85(1):93-105.
30. Mueller HS, Cohen L, Braunwald E, Forman S, Feit F, et al. Analyses of patient subgroups in the thrombolysis in myocardial infarction (TIMI) trial, phase II: predictors of early morbidity and mortality. *Circulation* 1992;85(4):1254-1264.
31. Rosenzweig BP, Donohue TJ, Attubato MJ, Feit F, Kronzon I. Left ventricle to ascending aorta communication following composite graft repair undetected by aortography: diagnosis by transesophageal echocardiography. *J Am Soc Echo*;1991;4:639-644.
32. Williams DO, Baim DS, Bates E, Bonan R, Bost JE, Cowley M, Faxon D, Feit F, and Kellett MA Jr. Coronary anatomic and procedural characteristics of patients randomized to coronary angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol* 1995;75(9):27C-33C.
33. Schwartzman DS, Attubato MJ, Feit. Interatrial septum and its role in embolization. In Capan LM, Miller S (eds.): *Embolism and Anesthesia*. *Anesthesiology Clinics of North America*. 1992;10:795-822.
34. Collen J, Kleinman N, and Feit F. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience. *Neurology* 1995;45(4):649-658.
35. Speyer JL, Green MD, Zeleniuch-Jacquotte A, Wernz JC, Rey MJ, Sanger J, Kramer E, Ferrans V, Hochster H, Meyers M, Blum RH, Feit F, Attubato MJ, Burrows W, Muggia FM. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. *J Clin Onc*. 1992;10:117-27.
36. Attubato MJ, Katz ES, Feit F, Bernstein NE, Schwartzman DS, Kronzon I. Venous changes occurring during the Valsalva maneuver: Evaluation by intravascular ultrasound. *Am*

- J Cardiol 1994;74:408-410.
37. Keller NM, and Feit F: Atherosclerotic Heart Disease in the Elderly. *Current Opinion in Cardiology* 1995;10:427-433.
 38. The BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. *N Engl J Med* 1996;335:217-225.
 39. Alderman E, Bourassa M, Brooks MM, Califf R, Chaitman B, Detre K, Faxon D, Feit F, Frye R, Hardison R, Holmes D, Holubkov R, Kouchoukos N, Krone R, Rogers W, Rosen AD, Schaff H, Schwartz L, Siewers AS, Sopko G, Sutton-Tyrrell K, and Whitlow P. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. *Circulation* 1997;96:1761-1769.
 40. Keller NM, and Feit F: Coronary Artery Disease in the Geriatric Population. *Progress in Cardiovascular Disease* 1996;38:407-418.
 41. Keller NM, and Feit F: New Approaches to thrombolysis in acute MI. *J Crit Illness* 1998;13(9):541-555.
 42. Keller NM, and Feit, F: Thrombolytic therapy in acute MI: Update on adjuvants. *J Crit Illness* 1998;13(10):646-652.
 43. Bittl JA and Feit F. A Randomized Comparison of Bivalirudin and Heparin in Patients Undergoing Coronary Angioplasty for Postinfarction Angina. *Am J Cardiol* 1998. (In press).
 44. Detre K, Guo P, Califf RC, Sopko G, Bach R, Holubkov R, Bourassa MG, Rosen A, Krone RJ, Frye R, and Feit F. Coronary revascularization in diabetic patients: A comparison of the randomized and observational components of BARI. *Circulation* 1998 (in press).
 45. Stadius M, Kip K, Jacobs AK, Feit F, Berger P, Lesperance J, Krone RJ, Dimas A, Baker W, Weiss M, Ping G, Faxon D, Alderman E, Williams D, Detre K. Angiographic suitability for balloon angioplasty in patients with multivessel coronary artery disease: A model from the Bypass Angioplasty Revascularization Investigation (BARI). *Circulation* 1998 (In press).
 46. Feit F, Brooks MM, Sopko G, Keller NM, Rosen A, Krone R, Berger P, Shemin R, Attubato MJ, Williams DO, Frye R, and Detre K. Long term clinical outcome in the Bypass Angioplasty Revascularization Investigation Registry: Comparison with the Randomized Trial. (1999 submitted to *Circulation*).

ABSTRACTS:

1. Shenkman L, Saito M, Feit F, Goldstein M. Reduced number of cardiac beta adrenergic receptors in rat pheochromocytoma. *Clin Res* 1979;27:595A.
2. Feit F, Fox AC, Snively S, et al. Nucleoside release reflects changing or prolonged regional myocardial ischemia. *Clin Res* 1980;28:168A.
3. Nicosia T, Mercurio P, Feit F, Fox AC. Sinus node function quadraplegics. *Am J Cardiol* 1981;47:393.
4. Rentrop KP, Blanke H, Feit F, et al. Die Mount Sinai/Bellevue Reperfusionstudie. Ergebnisse der randomisierten pilotstudie. 89. Tagung der Deutschen Gesellschaft für Innere Medizin 1983;A134.
5. Rey M, Siegel S, Feit F, et al. Late ventricular ectopy in the Mt. Sinai-NYU myocardial infarct reperfusion trial. *Circulation* 1983;68:III-410.
6. Murphy-Chutorian DR, Wexman MP, Grieco AJ, Heininger JA, Glassman E, Gaull GE, Feit F, et al. Methionine intolerance: a newly identified risk factor for coronary artery disease. *J Am Coll Cardiol* 1984;3:572.
7. Rentrop KP, Feit F, Schneider R, Blanke H, Stecy P. Mt.Sinai/New York University randomized reperfusion trial: pilot phase. *J Am Coll Cardiol* 1984;3:52.
8. Levin RI, Feit F, Jaffe EA. The physiologic response to nitroglycerin is not mediated by prostacyclin. *Clin Res* 1985;33:520A.
9. Frimer RB, Rapoport DM, Goodfield P, Feit F, et al. Diffusion capacity and its partition in the evaluation of unexplained pulmonary hypertension. *Am Rev of Resp Disease* 1985;131:A402.
10. Levin RI, Feit F, Jaffe EA. The effect of aspirin on the physiologic response to nitroglycerin. *Circulation* 1985;72:III-460.
11. Sherman W, Rey M, Feit F, et al. Correlation of left ventricular function and electrocardiography after myocardial reperfusion. *Circulation* 1986;74:II-479.
12. Rentrop KP, Feit F, Sherman W, et al. The Mt.Sinai-NYU reperfusion trial; ejection fraction effects. *Circulation* 1986;74:II-366.
13. Rentrop KP, Thornton J, Feit F, Cohen M, Cohen B. Recrutable collaterals predicted by lesion severity. *J Am Coll Cardiol* 1987;9:182A.

14. Rentrop KP, Feit F. The Second Mt.Sinai-NYU trial; main end points. *J Am Coll Cardiol* 1987;9:239A.
15. Speyer JL, Stecy P, Rey M, Kramer E, Sanger J, Feit F, et al. ICRF-187 prevents doxorubicin cardiotoxicity: results of a randomized clinical trial. *ASCO* 1987;6:28.
16. Fox SN, Reitano JM, Rey MJ, Goodfield P, Feit F. ST-segment depression manifested only in the post exercise phase as an indicator of coronary disease. *Clin Res* 1987;35:278A.
17. Feit F, Sherman W, Stecy P, et al. Incidence and significance of the left circumflex coronary artery as the cause of acute myocardial infarction. *Circulation* 1987;76:IV-122.
18. Rentrop KP, Feit F, Sherman W, Thornton JC. Major complications and interventions in the Mt.Sinai/NYU reperfusion trial. *Circulation* 1987;76:IV-1.
19. Feit F, Sherman W, Stecy P, et al. The Mt.Sinai-NYU Reperfusion trial: frequency and significance of subtotal stenosis of the infarct related artery prior to therapy. *Circulation* 1987;76:IV-123.
20. Rentrop KP, Thornton JC, Van Buskirk M, Feit F. Collateral flow preserves left ventricular function during acute ischemia in man. *J Am Coll Cardiol* 1988;11:104A.
21. Rentrop KP, Feit F, the Mt. Sinai-NYU Reperfusion Study Group. The second Mt.Sinai-NYU reperfusion trial: relatively late thrombolytic therapy is beneficial in patients with collaterals, but not in those with subtotal lesions. *J Am Coll Cardiol* 1988;11:187A.
22. Rentrop KP, Feit F, Sherman W, Thornton JC. Initial ejection fraction and collaterals determine benefit of relatively late thrombolytic therapy. *Circulation* 1988;78:II-127.
23. Feit F, Rey M, Sherman W, et al. Does anterior ST-depression in acute inferior wall MI have predictive value? *Circulation* 1988;78:II-212.
24. Feit F, Rey M, Sherman W, et al. The second Mt.Sinai-NYU reperfusion trial: incidence and significance of isolated ST-depression at screening. *Circulation* 1988;78:II-212.
25. Bovill E, Stump D, Tracy R, Collen D, Robertson T, Terrin M, Chesebro J, Feit F, et al. Dose response relationship of rt-PA infusion to induction of systemic fibrin(ogen)olysis in the NHLBI thrombolysis in myocardial infarction (TIMI) trial. *J Am Coll Cardiol* 1989;13:198A.
26. Rentrop KP, Feit F, Sherman W, Thornton J. Bimodal time course of collateral development in acute myocardial infarction. *J Am Coll Cardiol* 1989;13:45A.
27. Rentrop KP, Feit F, Sherman W, et al. Spontaneous recanalization is rare 2-14 hours after

- acute myocardial infarction. *Circulation* 1989;80:II-645.
28. Feit F, Mueller HS, Ross R, et al. Coronary angiography and angioplasty in the conservative arm of TIMI-IIB: a comparison of primary and satellite hospitals. *Circulation* 1989;80:II-625.
 29. Bovill E, Terrin M, Berke A, Bryant M, Collen D, Feit F, et al. Major hemorrhagic events and treatment with intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) II trial. *Blood* 1989; In press.
 30. McKendall G, Attubato MJ, Drew TM, Feit F, et al. Improved infarct artery patency using a new modified regimen of tPA: results of the pre-hospital administration of tPA (PATS) pilot trial. *J Am Coll Cardiol* 1990;15:3A.
 31. Rentrop KP, Feit F, Thornton JC, Mt. Sinai-NYU Reperfusion Study Group. The protective potential of collaterals depends on the time of their development. *J Am Coll Cardiol* 1990;15:202A.
 32. Feit F, Rey MJ, Sherman W, et al. Right ventricular involvement in acute myocardial infarction: a report from the second Mt. Sinai-NYU reperfusion trial. *J Am Coll Cardiol* 1990;15:218A.
 33. Rentrop KP, Feit F, Thornton JC, Mt. Sinai-NYU reperfusion trial. *J. Am Coll Cardiol* 1990;15:221A.
 34. Feit F, Rey MJ, Sherman W, et al. Late thrombolytic therapy improves thallium uptake in acute myocardial infarction: a report from the second Mt. Sinai-NYU reperfusion trial. *J Am Coll Cardiol* 1990;15:221A.
 35. Feit F, Attubato MJ, Finkle JK, Spadaro LA. Coronary angioplasty can be routinely performed as an extension of diagnostic angiography. *Chest* 1990;98:14S.
 36. Feit F, Davis K, Kennedy JW, for the NHLBI Balloon Valvuloplasty Registry. Percutaneous balloon pulmonic and tricuspid valvuloplasty in adults. *Circulation* 1990;82:III-78.
 37. Rentrop KP, Feit F, Thornton JC. Infarct artery identity does not predict successful thrombolysis. *Circulation* 1990;82:III-254.
 38. Dean LA, Davis K, Feit F, et al. Complications and mortality of percutaneous balloon mitral commissurotomy: report from the NHLBI balloon valvuloplasty registry. *Circulation* 1990;82-III-545.
 39. Feit F, Breed J, Anderson JL, et al. A randomized, placebo-controlled, trial of tissue

- plasminogen activator in elderly patients with acute myocardial infarction. *Circulation* 1990;82:III-666.
40. Berger PB, Ruocco NA, Ryan TJ, Diver DJ, Frederick M, Sharaf B, Feit F, Attubato MJ, Faxon DP. Incidence and significance of mitral regurgitation following first myocardial infarction treated with rt-PA; results from TIMI II. *J Am Coll Cardiol* 1991;17:185A.
 41. McKendall GR, Attubato MJ, Drew TM, Feit F, Sharaf BL, Thomas ES, Williams DO. Importance of the 90 minute angiographic flow grade in predicting subsequent infarct artery patency following thrombolytic therapy. *J Am Coll Cardiol* 1991;17:247A.
 42. Attubato MJ, Feit F, Stecy PJ, Ferrans V, Rey MJ, Zeleniuch-Jacquotte A, Green MD, Speyer JL. Histologic evidence of a cardioprotective effect of ICRF-187: results of a randomized trial in women receiving doxorubicin for breast cancer. *Circulation* 1991;84:II-632.
 43. Attubato MJ, Katz ES, Feit F, Bernstein N, Schwartzman D, Kronzon I. Venous changes occurring during the Valsalva maneuver: An intravascular ultrasound study. *Circulation* 1992;86:I-871.
 44. Slater J, Attubato MJ, Feit F, Mickel M, Kronzon I, for the NHLBI Balloon Valvuloplasty Registry. Temporary improvement after mitral balloon commissurotomy: Hemodynamic and angiographic correlates. *Circulation* 1993;88:I-351.
 45. Attubato MJ, Feit F, Bost JE, Verdinelli I, Rosen A, Jacobs AK, Weiner BH, Rogers WJ, and the Bypass Angioplasty Revascularization Investigation (BARI) Group. The relationship between coronary risk factors and the angiographic characteristics of coronary artery lesions. *J Am Coll Cardiol* 1994;484A.
 46. Attubato MJ, Slater J, Feit F, Bilyk F, Mickel M, Kronzon I, for the NHLBI Balloon Valvuloplasty Registry. Temporary improvement after balloon mitral commissurotomy: Incidence, demographics and clinical predictors. *JACC* 1994;61A.
 47. Kronzon I, Slater J, Attubato MJ, Feit F, Mickel M, for the NHLBI Balloon Valvuloplasty Registry. Echocardiographic correlates of only temporary improvement after balloon commissurotomy. *JACC* 1994;194A.
 48. Detre K, Rosen A, Jones R, Rogers W, Mock M, Faxon D, Bourassa M, Feit F, Cowley M, and Loop F. Is five year mortality different for treatment by choice versus random assignment in the Bypass Angioplasty Revascularization Investigation (BARI). *JACC* 1996;26:243A.
 49. Applebaum RM, Kronzon I, Attubato MJ, and Feit F. Three dimensional ultrasonic imaging of femoral arterial pseudoaneurysms. *JACC* 1997;521A.

50. Cannon L, Senior D, Feit F, Attubato M, Rosenberg J, O'Donnell M, Hirst J, Gibson M. Preliminary results from the intermediate Vessel Atherectomy Trial (IVAT). TCT and Am J Cardiol 1997.
51. Al-Meusa EN, O'Donnell M, Hirst J, Ryan K, Gibson M, and Feit F. Directional atherectomy normalized PTCA Guidewire velocity in the Intermediate Vessel Atherectomy Trial (IVAT). AHA 1997 abstract.
52. Jacobs AK, Bourassa MG, Kip, KE, Sopko G, Jones RH, Roubin GS, Alderman EL, Feit F, and Detre K. Is intended revascularization an accepted strategy? The Bypass Angioplasty Revascularization Investigation (BARI). American Heart Association 1997 (abstract).
53. Feit F, Weitz S, Cascade E, Karweit J, Schwartz. Predictors of In-hospital: events after Percutaneous Intervention. Am J Cardiol 1998;82(Suppl7A):30S.
54. Feit F, and Bittl J. Randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. American Heart Association 1998.
55. Kip K, Bourassa, Jacobs AK, Alderman EL, Weiner BH, Feit F, Weiss M, Schwartz L, Whitlow P, and Detre K. Influence of pre-PTCA strategy and initial PTCA result in patients with multivessel disease: The Bypass Angioplasty Revascularization Investigation (BARI). American Heart Association 1998.
56. Flachskampf FA, Ziada KM, Pieper M, Crowe T, Nissen SE, Tuzcu M, Brodie BR, Griffin J, Feit F, Constantini C, Mintz GS, Grines C, and Stone G. Do interventionalists underutilize devices during acute infarct intervention? Comparison of angiographic and intravascular ultrasound measures form the PAMI Stent randomized trial. American College of Cardiology 1999 (abstract).
57. Keller NM, Los Vegas V, Feit F, and Winer HE. Percutaneous coronary intervention (PCI) in elderly patients with acute MI. International Congress on Heart Disease 1999 (poster).